Skip to Main Content

Topical Antibacterial Agents for Prevention of COVID-19

Conditions

COVID-19 Outpatient

Phase COVID-I

What is the purpose of this trial?

The primary objective of this study is to determine whether intranasal application of aminoglycoside (Neosporin) increases local nasal innate immune responses compared to placebo control in healthy participants.

  • Trial with
    Bill and Melinda Gates Foundation
  • Start Date
    08/01/2022
  • End Date
    09/30/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/07/2022
  • Study HIC
    #2000032248